Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 10, pp 1431–1443 | Cite as

Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis

  • Carlos AlvesEmail author
  • Diogo Mendes
  • Francisco Batel Marques
Pharmacoepidemiology and Prescription

Abstract

Purpose

Tendinopathy is a known adverse reaction associated to fluoroquinolones, but a meta-analysis was not yet published. The aim of this study was to conduct a systematic review and a meta-analysis of the scientific evidence evaluating the risk of tendon injury associated with fluoroquinolones.

Methods

A literature search was conducted to identify observational studies which reported results on the risk of Achilles tendon rupture (ATR), risk of Achilles tendinitis (AT), or risk of any tendon disorders (ATD). A meta-analysis was performed by pooling odds ratios (ORs) with their 95% confidence intervals (CIs).

Results

Fifteen studies were included in the meta-analysis. Treatment with fluoroquinolones was associated with an increased risk of ATR (OR 2.52 (95% CI 1.81–3.52), p < 0.001, I2 = 76.7%), an increased risk of AT (OR 3.95 (95% CI 3.11–5.01), p < 0.001, I2 = 0%), and increased risk of ATD (OR 1.98 (95% CI 1.62–2.43), p < 0.001, I2 = 84.5%). The initial risk estimates remained statistically significant among patients aged ≥ 60 years old. Risk estimates did not significantly change after depending on the concomitant use of corticosteroids or studies methodological quality assessment. The analysis according to the type of fluoroquinolones was only possible for ATR, which were ofloxacin and norfloxacin were found to increase the risk of this outcome, but not ciprofloxacin and levofloxacin.

Conclusions

The results of this meta-analysis confirm the risk of tendon injuries associated with fluoroquinolones. Older age and concomitant use of corticosteroids seem to be additional risk factors for tendinopathy.

Keywords

Fluoroquinolones Tendinopathy Pharmacovigilance Risk assessment Meta-analysis 

Notes

Author contribution

Carlos Alves conceived and designed the study, performed research, analyzed data, and wrote the paper. Diogo Mendes and Francisco Batel Marques conceived the study and wrote the paper.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2713_MOESM1_ESM.docx (21 kb)
Supplemental Figure 1 (DOCX 21 kb)
228_2019_2713_MOESM2_ESM.docx (17 kb)
Supplemental Figure 2 (DOCX 17 kb)
228_2019_2713_MOESM3_ESM.docx (22 kb)
Supplemental Figure 3 (DOCX 21 kb)
228_2019_2713_MOESM4_ESM.docx (16 kb)
Supplemental Figure 4 (DOCX 15 kb)
228_2019_2713_MOESM5_ESM.docx (16 kb)
Supplemental Figure 5 (DOCX 15 kb)
228_2019_2713_MOESM6_ESM.docx (16 kb)
Supplemental Figure 6 (DOCX 16 kb)
228_2019_2713_MOESM7_ESM.doc (64 kb)
Supplemental Table 1 (DOC 64 kb)
228_2019_2713_MOESM8_ESM.docx (17 kb)
Supplemental Table 2 (DOCX 17 kb)
228_2019_2713_MOESM9_ESM.docx (18 kb)
Supplemental Table 3 (DOCX 17 kb)

References

  1. 1.
    Wolfson JS, Hooper DC (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324:384–394CrossRefGoogle Scholar
  2. 2.
    Khaliq Y, Zhanel GG (2003) Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 36:1404–1410CrossRefGoogle Scholar
  3. 3.
    Tomé AM, Filipe A (2011) Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 34:465–488CrossRefGoogle Scholar
  4. 4.
    Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 33:303–314CrossRefGoogle Scholar
  5. 5.
    Pierfitte C, Gillet P, Royer RJ (1995) More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med 332:193CrossRefGoogle Scholar
  6. 6.
    US US Food and Drug Administration. FDA News Release. U.S. Food and Drug Administration. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm612995.htm. Accessed 14 May 2019
  7. 7.
    US Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. http://wayback.archive-it.org/7993/20170112032310/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm. Accessed 14 May 2019
  8. 8.
    European Medicines Agency. Disabling and potentially permanent side effects lead to uspension or restrictions of quinolone and fluoroquinolone antibiotics. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products. Accessed 14 May 2019
  9. 9.
    Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X (2019) Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case-control study. Clin Drug Investig 39:205–213CrossRefGoogle Scholar
  10. 10.
    Stephenson AL, Wu W, Cortes D, Rochon PA (2013) Tendon injury and fluoroquinolone use: a systematic review. Drug Saf 36:709–721CrossRefGoogle Scholar
  11. 11.
    van der Vlist AC, Breda SJ, Oei EHG, Verhaar JAN, de Vos RJ (2019) Br J Sports Med.  https://doi.org/10.1136/bjsports-2018-099991
  12. 12.
    Yu X, Jiang DS, Wang J, Wang R, Chen T, Wang K, Cao S, Wei X (2019) Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis. Drug Saf.  https://doi.org/10.1007/s40264-019-00828-z
  13. 13.
    Persson R, Jick S (2019) Clinical implications of the association between fluoroquinolones and tendon rupture: the magnitude of the effect with and without corticosteroids. Br J Clin Pharmacol 85:949–959CrossRefGoogle Scholar
  14. 14.
    Nyyssönen T, Lantto I, Lüthje P, Selander T, Kröger H (2018) Drug treatments associated with Achilles tendon rupture. A case-control study involving 1118 Achilles tendon ruptures. Scand J Med Sci Sports 28:2625–2629CrossRefGoogle Scholar
  15. 15.
    Daneman N, Lu H, Redelmeier DA (2015) Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 5:e010077CrossRefGoogle Scholar
  16. 16.
    Ioannidis JP, Patsopoulos NA, Rothstein HR (2008) Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 336:1413–1415CrossRefGoogle Scholar
  17. 17.
    Smith TC, Spiegelhalter DJ, Thomas A (1995) Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 14:2685–2699CrossRefGoogle Scholar
  18. 18.
    Berlin JA (1995) Invited commentary: benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Am J Epidemiol 142:383–387CrossRefGoogle Scholar
  19. 19.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRefGoogle Scholar
  20. 20.
    U.S. National Library of Medicine. Medical Subject Headings 2019. U.S. National Library of Medicine. https://meshb.nlm.nih.gov/search. Accessed 14 May 2019
  21. 21.
    ICH MedDRA Maintenance and Support Services Organization (MSSO). International Council for Harmonisation of technical requirements for Pharmaceuticals for Human use (ICH). https://www.meddra.org/. Accessed 14 May 2019
  22. 22.
    Elsevier. Embase Indexing and Emtree. https://www.elsevier.com/solutions/embase-biomedical-research. Accessed 14 May 2019
  23. 23.
    Wells GA, Shea B, O’Connell D et al (2014). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 14 May 2019
  24. 24.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefGoogle Scholar
  25. 25.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefGoogle Scholar
  26. 26.
    B Publication bias (2009) In: Borenstein M, Hedges LV, JPT H, Rothstein HR (eds) Introduction to meta-analysis. Wiley, Chichester, pp 277–291Google Scholar
  27. 27.
    van der Linden PD, van de Lei J, Nab HW, Knol A, Stricker BH (1999) Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 48:433–437CrossRefGoogle Scholar
  28. 28.
    Sode J, Obel N, Hallas J, Lassen A (2007) Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 63:499–503CrossRefGoogle Scholar
  29. 29.
    Hori K, Yamakawa K, Yoshida N, Ohnishi K, Kawakami J (2012) Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan. Pharmacoepidemiol Drug Saf 21:886–889CrossRefGoogle Scholar
  30. 30.
    Humbyrd CJ, Bae S, Kucirka LM, Segev DL (2018) Incidence, risk factors, and treatment of Achilles tendon rupture in patients with end-stage renal disease. Foot Ankle Int 39:821–828CrossRefGoogle Scholar
  31. 31.
    Jupiter DC, Fang X, Ashmore Z, Shibuya N, Mehta HB (2018) The relative risk of Achilles tendon injury in patients taking quinolones. Pharmacotherapy 38:878–887CrossRefGoogle Scholar
  32. 32.
    Barge-Caballero E, Crespo-Leiro MG, Paniagua-Martín MJ, Muñiz J, Naya C, Bouzas-Mosquera A, Piñón-Esteban P, Marzoa-Rivas R, Pazos-López P, Cursack GC, Cuenca-Castillo JJ, Castro-Beiras A (2008) Quinolone-related Achilles tendinopathy in heart transplant patients: incidence and risk factors. J Heart Lung Transplant 27:46–51CrossRefGoogle Scholar
  33. 33.
    van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003) Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 163:1801–1807CrossRefGoogle Scholar
  34. 34.
    Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM (2006) Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf 15:784–792CrossRefGoogle Scholar
  35. 35.
    Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y (2012) Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 125:1228.e23–1228.e28CrossRefGoogle Scholar
  36. 36.
    Corrao G, Zambon A, Bertù L et al (2006) Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 29:889–896CrossRefGoogle Scholar
  37. 37.
    van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH (2002) Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 324:1306–1307CrossRefGoogle Scholar
  38. 38.
    Williams RJ 3rd, Attia E, Wickiewicz TL, Hannafin JA (2000) The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 28:364–369CrossRefGoogle Scholar
  39. 39.
    Tsai WC, Hsu CC, Chen CP et al (2011) Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res 29:67–73CrossRefGoogle Scholar
  40. 40.
    Shakibaei M, de Souza P, van Sickle D, Stahlmann R (2001) Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 75:369–374CrossRefGoogle Scholar
  41. 41.
    Pouzaud F, Bernard-Beaubois K, Thevenin M, Warnet JM, Hayem G, Rat P (2004) In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. J Pharmacol Exp Ther 308:394–402CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Laboratory of Social Pharmacy and Public Health, School of PharmacyUniversity of CoimbraCoimbraPortugal
  2. 2.AIBILI – Association for Innovation and Biomedical Research on Light and Image, CHAD – Centre for Health Technology Assessment and Drug ResearchCoimbra Regional Pharmacovigilance Unit (UFC)CoimbraPortugal

Personalised recommendations